Open an account

OS Therapies

OSTX · NYSE American

$1.26−$0.01 (−0.79%)TodayMarket closed ·
Prev close $1.27

About OSTX

OS Therapies, Inc. operates as a clinical stage biopharmaceutical company. The company is headquartered in Rockville, Maryland and currently employs 4 full-time employees. The company went IPO on 2024-08-01. Its pipeline includes two drug technologies: OST-HER2 and OST-tADC. Its lead asset, OST-HER2, is an off-the-shelf immunotherapy, which is a type of cancer treatment that helps one’s immune system fight cancer, comprised of a genetically weakened and modified strain of Listeria monocytogenes, a species of bacteria that causes the infection listeriosis, that expresses HER2 peptides. OST-tADC is a tunable ADC with a plug-and-play platform that features tunable pH-sensitive silicone linkers (SiLinkers). Its clinical-stage cancer immunotherapy programs also include OST-AXAL for human papilloma virus (HPV)-associated cancers; OST-503 for non-small cell lung cancer (NSCLC) & glioblastoma; and OST-PSA for prostate cancer.

Employees
4
Headquarters
Rockville, Maryland
Listed
Aug 1, 2024
Sector
Health Care
Industry
Biotechnology
Website
ostherapies.com

OSTX key statistics

Market cap
58.97M
Price-earnings ratio
0.00
Dividend yield
—
Average volume
760.60K
Volume
320.66K
Open price
$1.30
High today
$1.34
Low today
$1.26
52 Week high
$2.25
52 Week low
$1.15

OS Therapies (OSTX) at a glance

As of Oct 20, 2026, OS Therapies (OSTX) shares are priced at $1.26, giving the company a market cap of 58.97M and a price-to-earnings ratio of 0.00.

Today the stock has traded between $1.26 and $1.34. The current price is 0.4% above the day's low and 6.0% below its high.

Volume so far is 320.66K shares, below the average of 760.60K shares a day.

Over the past year OS Therapies has ranged from $1.15 to $2.25, and now sits 10% of the way up that range.

OS Therapies met or beat analyst EPS estimates in 1 of the last 8 quarters. In Q2 FY26 it reported -$0.20 per share against an estimate of -$0.2101.

The average analyst price target is $8.67, 588.1% above the current price, from 3 recent ratings.

Analyst ratings

Latest rating from each analyst over the past 12 months

100%of 3 analyst ratings say Buy
  • Buy100.0%
  • Hold0.0%
  • Sell0.0%
Price target · 6 analystsAvg $8.67
Low
$6.06
Now
$1.26
High
$13.65

OSTX earnings

Earnings per share, reported against the analyst estimate

Beat the estimate in 1 of the last 8 quarters, by 4.8% on average.

  1. Q3 FY24: reported -$0.18 per share against an estimate of -$0.1224
  2. Q4 FY24: reported -$0.24 per share against an estimate of -$0.1462
  3. Q1 FY25: reported -$0.24 per share against an estimate of -$0.0816
  4. Q2 FY25: reported -$0.19 per share against an estimate of -$0.1173
  5. Q3 FY25: reported -$0.21 per share against an estimate of -$0.1275
  6. Q4 FY25: reported -$0.50 per share against an estimate of -$0.1387
  7. Q1 FY26: reported -$0.27 per share against an estimate of -$0.1802
  8. Q2 FY26: reported -$0.20 per share against an estimate of -$0.2101

OSTX news

  • Vandana Singh

    OS Therapies Reports Significant Three-Year Survival Data for Bone Cancer Treatment

  • Vandana Singh

    OS Therapies Reports Strong Survival Data for Bone Cancer Treatment

  • Vandana Singh

    OS Therapies Says New Bone Cancer Data Strengthens Case For Regulatory Filings

  • Press releaseBusiness Wire

    OS Therapies Investor News: Rosen Law Firm Encourages OS Therapies Incorporated Investors to Inquire About Securities Class Action Investigation – OSTX

  • Press releaseBusiness Wire

    Rosen Law Firm Encourages OS Therapies Incorporated Investors to Inquire About Securities Class Action Investigation – OSTX

  • Press releasePRNewswire

    SHAREHOLDER ALERT: Purcell & Lefkowitz LLP Announces Shareholder Investigation of OS Therapies Incorporated (NYSE American: OSTX)

  • Avi Kapoor

    Why Quantum Computing Shares Are Trading Higher By Over 23%; Here Are 20 Stocks Moving Premarket

  • Press releaseNewsfile

    OS Therapies Announces Statistically Significant Positive Final 2-Year Overall Survival Data from Phase 2b Trial of OST-HER2 in the Prevention or Delay of Recurrent, Fully-Resected, Pulmonary Metastatic Osteosarcoma

Similar companies

Companies in the same industry as OS Therapies

Most active stocks

Highest trading volume today

Newly listed

Companies that went public in the past six weeks

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.